US20090169522A1 - Mesenchymal stem cells expressing tnf-a receptor - Google Patents

Abstract

Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10⁶cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.

Description

• This application claims priority based on application Ser. No. 60/759,157, filed Jan. 13, 2006, the contents of which are incorporated by reference in their entirety.
• This invention relates to mesenchymal stem cells. More particularly, this invention relates to mesenchymal stem cells which express tumor necrosis factor-alpha (TNF-α) receptors, and in particular, the tumor necrosis factor-alpha (TNF-{acute over (α)}) receptor Type I (TNFRI), in an amount of at least 13 pg/10⁶cells. Such mesenchymal stem cells inhibit lymphocyte proliferation.
• Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate readily into lineages including osteoblasts, myocytes, chondrocytes, and adipocytes (Pittenger, et al.,Science, Vol. 284, pg. 143 (1999); Haynesworth, et al.,Bone, Vol. 13, pg. 69 (1992); Prockop,Science, Vol. 276, pg. 71 (1997)). In vitro studies have demonstrated the capability of MSCs to differentiate into muscle (Wakitani, et al.,Muscle Nerve, Vol. 18, pg. 1417 (1995)), neuronal-like precursors (Woodbury, et al.,J. Neurosci. Res., Vol. 69, pg. 908 (2002); Sanchez-Ramos, et al.,Exp. Neurol., Vol. 171, pg. 109 (2001)), cardiomyocytes (Toma, et al.,Circulation, Vol. 105, pg. 93 (2002); Fakuda,Artif. Organs, Vol. 25, pg. 187 (2001)) and possibly other cell types. In addition, MSCs have been shown to provide effective feeder layers for expansion of hematopoietic stem cells (Eaves, et al.,Ann. N.Y. Acad. Sci., Vol. 938, pg. 63 (2001); Wagers, et al.,Gene Therapy, Vol. 9, pg. 606 (2002)). Recent studies with a variety of animal models have shown that MSCs may be useful in the repair or regeneration of damaged bone, cartilage, meniscus or myocardial tissues (DeKok, et al.,Clin. Oral Implants Res., Vol. 14, pg. 481 (2003)); Wu, et al.,Transplantation, Vol. 75, pg. 679 (2003); Noel, et al.,Curr. Opin. Investig. Drugs, Vol. 3, pg. 1000 (2002); Ballas, et al.,J. Cell. Biochem. Suppl., Vol. 38, pg. 20 (2002); Mackenzie, et al.,Blood Cells Mol. Dis., Vol. 27, pgs. 601-604 (2001)). Several investigators have used MSCs with encouraging results for transplantation in animal disease models including osteogenesis imperfecta (Pereira, et al.,Proc. Nat. Acad. Sci., Vol. 95, pg. 1142 (1998)), parkinsonism (Schwartz, et al.,Hum. Gene Ther., Vol. 10, pg. 2539 (1999)), spinal cord injury (Chopp, et al.,Neuroreport, Vol. 11, pg. 3001 (2000); Wu, et al.,J. Neurosci. Res., Vol. 72, pg. 393 (2003)) and cardiac disorders (Tomita, et al.,Circulation, Vol. 100, pg. 247 (1999). Shake, et al.,Ann. Thorac. Surg., Vol. 73, pg. 1919 (2002)). Importantly, promising results also have been reported in clinical trials for osteogenesis imperfecta (Horowitz, et al.,Blood, Vol. 97, pg. 1227 (2001); Horowitz, et al.Proc. Nat. Acad. Sci., Vol. 99, pg. 8932 (2002)) and enhanced engraftment of heterologous bone marrow transplants (Frassoni, et al.,Int. Society for Cell Therapy, SA006 (abstract) (2002); Koc, et al.,J. Clin. Oncol., Vol. 18, pgs. 307-316 (2000)).
• In addition, in vitro studies from different laboratories have shown that MSCs can inhibit T-cell proliferation either in mixed lymphocyte cultures or by other stimuli such as antigens and mitogens (Di Nicola, et al.,Blood, Vol. 99, pgs. 3638-3843 (2002); Tse, et al.,Transplantation, Vol. 75, pgs. 389-397 (2003); Aggarwal, et al.,Blood, Vol. 105, pgs. 1815-1822 (2005)). Recent in vitro data demonstrate further that MSCs decrease the secretion of pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α), and Interferon-γ (IFN-γ), and simultaneously increase production of anti-inflammatory cytokines Interleukin-10 (IL-10) and Interleukin-4 (IL-4) by immune cells. (Aggarwal, 2005). These results indicate that due to immunomodulatory and anti-inflammatory activities, MSCs can be beneficial for treatment of immunological responses which occur in graft-versus-host disease (GVHD), solid organ transplantation, and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. A clinical case report demonstrating the therapeutic effect of MSCs for acute GVHD supports strongly this hypothesis. (Le Blanc, et al.,The Lancet, Vol. 363, pgs. 1439-1441 (2004).)
• The TNF-α receptors are expressed on the surface of mesenchymal stem cells. Accumulated data indicate that TNF-α is an important regulator of mesenchymal stem cell function. Incubation of TNF-α with human mesenchymal stem cells in culture upregulates prostaglandin E2 (PGE₂) and keratinocyte growth factor (KGF) secretion, inducesindoleamine 2,3 deoxygenase (IDO) enzyme activity and stimulates cell migration. TNF-α has been shown to be present at wound and inflammatory sites, especially in organs targeted by graft-versus-host disease. (Koide, et al.,Transplantation, Vol. 64, pgs. 518-524 (1997); Kuroiwa, et al.,J. Clin. Invest., Vol. 107, pgs. 1365-1373 (2001); Deans, et al.,Exp. Hematol., Vol. 28, pgs. 875-884 (2002); Ellison, et al.,J. Clin. Immunol., Vol. 24, pgs. 197-211 (2004)). Thus, such data indicate that expression of TNF-α receptors by mesenchymal stem cells may be critical for immunosuppressive, immunomodulatory, anti-inflammatory, tissue-repairing, or wound-healing activities, as well as migration to sites of inflammation.
• There are two types of TNF-α receptors, or TNFRs: Type I (TNFRI), also known as p55, and Type II (TNFRII), also known as p75. (Tartaglia, et al.,Proc. Nat. Acad. Sci, Vol. 88, pgs. 9292-9296 (1991).) Both types of TNF-α receptors are present on MSCs; however, TNFRI is the predominant type. (Vancheri, et al.,Am. J. Respir. Cell Mol. Biol., Vol. 22, pgs. 628-634 (2000); Debets, et al.,Cytokine, Vol. 8, pgs. 80-88 (1996).)
• The invention now will be described with respect to the drawings wherein:
• FIG. 1 is a graph of the correlation between TNFRI expression and the ability of MSCs to inhibit PBMC proliferation in vitro;
• FIG. 2 is a graph showing TNFRI expression by human mesenchymal stem cells stored at −80° C., −70° C., −60° C., and −50° C.;
• FIG. 3 is a graph showing TNFRI expression and the ability to inhibit PBMC proliferation in vitro, of human mesenchymal stem cells stored at −80° C. and −50° C.; and
• FIG. 4 is a graph showing TNFRI expression by human mesenchymal stem cells stored at −135° C. or below, and then thawed and kept at room temperature for 6, 8, 24, or 32 hours.
• In accordance with an aspect of the present invention, there is provided a composition comprising mesenchymal stem cells. The mesenchymal stem cells express the TNF-{acute over (α)} receptor Type I (TNFRI) in an amount effective to inhibit the proliferation of lymphocytes. In one embodiment, the mesenchymal stem cells express TNFRI in an amount of at least 13 pg/10⁶cells. In another embodiment, the mesenchymal stem cells express TNFRI in an amount of at least 15 pg/10⁶cells. In yet another embodiment, the mesenchymal stem cells express TNFRI in an amount of at least 18 pg/10⁶cells.
• Although the scope of the present invention is not to be limited to any theoretical reasoning, Applicants have found that mesenchymal stem cells which express the TNF-{acute over (α)} receptor Type I in an amount from at least 13 pg/10⁶cells inhibit the proliferation of lymphocytes. Such mesenchymal stem cells are particularly useful in inhibiting immune responses, and more particularly such mesenchymal stem cells are useful in the treatment of graft-versus-host disease; solid organ transplant rejection such as, for example, heart transplant rejection, liver transplant rejection, pancreas transplant rejection, intestine transplant rejection, and kidney transplant rejection; and autoimmune diseases such as, for example, rheumatoid arthritis, multiple sclerosis, Type I diabetes, Crohn's disease, Guillain-Barré syndrome, lupus erythematosus, myasthenia gravis, optic neuritis, psoriasis, Graves' disease, Hashimoto's disease, Ord's thyroiditis, aplastic anemia, Reiter's syndrome, autoimmune hepatitis, primary biliary cirrhosis, antiphospholipid antibody syndrome, opsoclonus myoclonus syndrome, temporal arteritis, acute disseminated encephalomyelitis, Goodpasture's syndrome, Wegener's granulomatosis, coeliac disease, pemphigus, polyarthritis, warm autoimmune hemolytic anemia, and scleroderma.
• In one embodiment, the mesenchymal stem cells are obtained from a mammal. The mammal may be a primate, including human and non-human primates.
• The mesenchymal stem cells may be a homogeneous composition or may be a mixed cell population enriched in MSCs. Homogeneous mesenchymal stem cell compositions may be obtained by culturing adherent marrow or periosteal cells, and the mesenchymal stem cells may be identified by specific cell surface markers which are identified with unique monoclonal antibodies. A method for obtaining a cell population enriched in mesenchymal stem cells is described, for example, in U.S. Pat. No. 5,486,359. Alternative sources for mesenchymal stem cells include, but are not limited to, blood, skin, cord blood, muscle, fat, bone, and perichondrium.
• The amount of cellular TNF-α receptor, such as TNF-α receptor Type I, that is expressed in a culture of mesenchymal stem cells may be determined by methods known to those skilled in the art. Such methods include, but are not limited to, quantitative assays such as quantitative ELISA assays, for example. It is to be understood, however, that the scope of the present invention is not to be limited to any particular method for determining the amount of TNF-α receptor.
• In one embodiment, the amount of TNF-α receptor expressed by a culture of mesenchymal stem cells is determined by an ELISA assay. In such an assay, a cell lysate from a culture of mesenchymal stem cells is added to a well of an ELISA plate. The well may be coated with an antibody, either a monoclonal or a polyclonal antibody(ies), against the TNF-α receptor. The well then is washed, and then contacted with an antibody, either a monoclonal or a polyclonal antibody(ies), against the TNF-α receptor. The antibody is conjugated to an appropriate enzyme, such as horseradish peroxidase, for example. The well then may be incubated, and then is washed after the incubation period. The wells then are contacted with an appropriate substrate, such as one or more chromogens. Chromogens which may be employed include, but are not limited to, hydrogen peroxide and tetramethylbenzidine. After the substrate(s) is (are) added, the well is incubated for an appropriate period of time.
• Upon completion of the incubation, a “stop” solution is added to the well in order to stop the reaction of the enzyme with the substrate(s). The optical density (OD) of the sample then is measured. The optical density of the sample is correlated to the optical densities of samples containing known amounts of TNF-α receptor in order to determine the amount of TNF-α receptor expressed by the culture of mesenchymal stem cells being tested.
• Thus, the present invention provides for the selection of a population of mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10⁶cells. Such selected mesenchymal stem cells then may be admixed with an appropriate pharmaceutical carrier for treatment of the diseases and disorders mentioned hereinabove. For example, the mesenchymal stem cells may be administered as a cell suspension including a pharmaceutically acceptable liquid medium for injection.
• The mesenchymal stem cells of the present invention are administered to an animal in an amount effective to treat one or more of the above-mentioned diseases or disorders in the animal. The animal may be a mammal, and the mammal may be a primate, including human and non-human primates. The mesenchymal stem cells may be administered systemically, such as, for example, by intravenous, intraarterial, or intraperitoneal administration. The exact dosage of mesenchymal stem cells to be administered is dependent upon a variety of factors, including, but not limited to, the age, weight, and sex of the patient, the disease(s) or disorder(s) being treated, and the extent and severity thereof.
• The invention now will be described with respect to the following examples; however, the scope of the present invention is not intended to be limited thereby.
EXAMPLE 1
• In order to investigate the role of TNFRI on the immunosuppressive hMSC activity, hMSCs were transfected transiently by antisense TNFRI type oligonucleotides with the purpose to decrease TNFRI expression (Shen et al.,J. Biol. Chem., Vol. 272, pgs. 3550-3553 (1997)). In order to reach different degrees of TNFRI expression inhibition, three different concentrations of oligonucleotides were used for transfection experiments. Non-transfected MSCs and MSCs transfected with a sense oligonucleotide were used as controls. TNFRI expression on hMSCs was analyzed in cell lysates by ELISA, and effect of reduction in TNFRI expression on hMSC capacity to inhibit hPBMC proliferation in vitro was investigated.
• Human bone marrow-derived MSCs atPassage 5 from 7 different donors were used for analysis. Cells were obtained from bone marrow aspirates, and isolated using hespan. The cells then were cultured throughPassage 5, and frozen in a standard cryopreservation solution containing 5% human serum albumin (HSA) and 10% dimethylsulfoxide in Plasmalyte A. (Baxter) The cells were stored at −80° C. prior to analysis. On the day of the experiment, the hMSCs were thawed, counted, and plated into 6-well tissue culture plates at 2.5×10⁵cells/well. After overnight incubation, cells were transfected with TNFRI sense or antisense oligonucleotides at concentrations of 1.25, 2.5 and 5 pg/mL according to the transfection reagent manufacturer's protocol (Invitrogen, the Cellfectin transfection reagent product insert). At 24 hours post-transfection, the cells were collected from the plates. One group of cells was lysed, and expression of TNFRI in cell lysates was analyzed by ELISA according to the sTNFRI ELISA protocol (R&D Systems, product insert). TNFRI expression was expressed in pg of receptor per 1×10⁶cells.
• For the ELISA assay, 2.5×10⁵MSCs per well were lysed directly in wells using 250 μl/well of Cell Lytic-mammalian cell lysis/extraction reagent (Sigma, Catalog No. C-2978) containing a complete protein inhibitor cocktail (Roche). The cell lysates then were centrifuged for 10 minutes at 12,000-14,000 rpm in an Eppendorf centrifuge to remove insoluble material from the lysis buffer solution. The cell lysates then were collected in a new tube for use in the ELISA assay.
• An alternative method of cell lysis, i.e., lysis of cell pellets in tubes, also was carried out for frozen cells and for cells collected from tissue culture plates or flasks. Both methods, direct cell lysis in culture plates and lysis of cell pellets in tubes, gave comparable results.
• A commercially available ELISA kit, Quantikine®, Human sTNFRI (Catalog No.DRT 100, R&D Systems) was used for the detection of TNFRI in cell lysates. This assay provides for the measurement of both soluble as well as cell-associated TNFRI (Qjwang, et al.,Biochemistry, Vol. 36, pg. 6033 (1997).) The assay employs the quantitative sandwich enzyme immunoassay technique. The assay employs a microplate that includes wells that have been pre-coated with a monoclonal antibody specific for TNFRI. TNFRI present in calibrator samples, quality control samples, or samples of MSC cell lysates is captured by the immobilized TNFRI antibody. After washing away any unbound substances, enzyme-linked polyclonal antibodies specific for TNFRI is added to the wells. Following a wash step to remove any unbound enzyme-linked antibody, a substrate solution was added to the wells, and color develops in proportion to the amount of bound TNFRI. The color development then is stopped, and the intensity of the color is measured using an ELISA reader.
• The details of the ELISA are given hereinbelow.
• 50 μl of assay diluent HD1-7, a buffered protein base with preservative, were added to the wells of an ELISA plate. The wells were coated with a monoclonal antibody specific for TNFRI. 200 μl of either calibrator samples (containing 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.25 pg/ml, 15.625 pg/ml, or 7.813 pg/ml of soluble human TNFRI), quality control samples (containing 45 pg/ml, 100 pg/ml, or 250 pg/ml of human TNFRI), or cell lysates then were added to the wells. Prior to the addition of the calibration and quality control sample to the wells, such samples were treated with the Cell Lytic-mammalian cell lysis extraction agent (Sigma) and complete protein inhibitor cocktail (Roche) as hereinabove described. The plate then was covered with an adhesive strip, and incubated for 2 hours ±10 minutes at room temperature.
• The liquid then was decanted from each well by inverting the plate over a sink, and then the plate was washed three times. The plate is washed each time with 400 μl of a wash buffer added to each well. Residual liquid was removed by inverting the plate and blotting.
• 200 μl of soluble TNFRI polyclonal antibodies conjugated to horseradish peroxidase then were added to each well. The plate then was incubated for 2 hours ±10 minutes at room temperature. The liquid then was decanted from each well, and each well was washed three times with 400 μl of wash buffer as hereinabove described.
• 200 μl of a substrate solution of stabilized hydrogen peroxide and stabilized tetramethylbenzidine chromogen then were added to each well. The plate then was incubated for 20 minutes ±10 minutes at room temperature in the dark. 50 μl of a solution of 2N sulfuric acid then were added to each well. The optical density (OD) of each sample then was measured within 30 minutes with a 450 nm test and a 570 nm reference filter. The optical density values then were correlated to the amounts of TNFRI in the cell lysate samples.
• Quantitation was achieved by comparing the signal from samples of MSC cell lysates to TNFRI standards assayed at the same time. Each ELISA run provided a calibration curve and included duplicate quality control samples plated in front and after test samples. Quality control samples were used for ELISA run validity assessment. TNFRI expression data were expressed in picograms of receptor per 1×10⁶cells. The raw data (in pg/ml) reflect TNFRI in picograms per 1×10⁶cells (2.5×10⁵cells were lysed in 250 μl of the lysis reagent, thus corresponding to 1×10⁶cells/ml).
• The ELISA values for the calibration samples are given in Table 1 below.

• TABLE 1
  Calculations for ELISA run calibration standards

  	Theoretical				Back
  	Concentration				Calculated	Calculated Mean
  	of		OD		Concentration	Concentration
  Calibrator	Calibratiors	OD*	Mean	Standard	for Standards	for Standards
  Sample	(pg/mL)	Values	Value	Deviation	(pg/mL)	(pg/mL)	% DFT*	% CV*

  St01	500	2.431	2.437	0.008	498.003	499.923	−0.015	0.3
  		2.443			501.842
  St02	250	1.487	1.476	0.016	252.746	250.306	0.123	1.1
  		1.464			247.867
  St03	125	0.804	0.815	0.015	122.64	124.447	−0.442	1.8
  		0.825			126.255
  St04	62.5	0.453	0.442	0.016	64.774	63.024	0.839	3.5
  		0.431			61.274
  St05	31.25	0.25	0.239	0.016	32.749	30.939	−0.996	6.8
  		0.227			29.128
  St06	15.625	0.143	0.145	0.002	15.765	16.007	2.446	1.5
  		0.146			16.249
  St07	7.813	0.092	0.093	0.001	7.368	7.537	−3.528	1.5
  		0.094			7.706
  *Note:
  OD—optical density;
  % DFT—% Difference from Theoretical;
  CV %—% Coefficient of Variance

• The ELISA values for the quality control samples are given in Table 2 below.

• TABLE 2
  Calculations for ELISA run Quality Control (QC) samples

  					Back
  	Theoretical				Calculated	Calculated Mean
  	Concentrations		OD		Concentration	Concentration
  QC	for QCs	OD*	Mean	Standard	for QCs	for QCs
  Samples:	(pg/mL)	Values	Value	Deviation	(pg/mL)	(pg/mL)	% DFT*	% CV*

  Front
  QCs
  QC01	45	0.366	0.372	0.008	50.991	51.938	15.417	2.3
  		0.378			52.884
  QC02	100	0.753	0.733	0.028	113.944	110.572	10.572	3.9
  		0.713			107.2
  QC03	250	1.503	1.509	0.008	256.165	257.454	2.982	0.6
  		1.515			258.742
  Back
  QCs
  QC01	45	0.315	0.332	0.024	42.964	45.638	1.418	7.2
  		0.349			48.312
  QC02	100	0.712	0.698	0.021	107.033	104.609	4.609	2.9
  		0.683			102.185
  QC03	250	1.547	1.558	0.015	265.671	267.967	7.187	1
  		1.568			270.263
  *Note:
  OD—optical density;
  % DFT—% Difference from Theoretical;
  CV %—% Coefficient of Variance

• Based on the ELISA values for the calibration and quality control samples shown in Tables 1 and 2 hereinabove, TNFRI expression in pg per 1×10⁶cells for samples of mesenchymal stem cells from the donors was determined. As described hereinabove, the mesenchymal stem cells from each donor were non-transfected, or transfected with a TNFRI sense or antisense oligonucleotide at a concentration of 1.25, 2.5, or 5 μg/ml. The ELISA values and the amount of TNFRI expressed by each of the mesenchymal stem cell samples from each of the donors are given in Table 3 below.

• TABLE 3
  Calculations for ELISA run test samples

  hMSC			OD		Calculated	Mean	TNFRI in
  Donor		OD*	Mean		Concentration	Concentration	pg per
  #	Sample description:	Values	Value	SD*	(pg/mL)	(pg/mL)	1 × 106cells	% CV*

  24	Control	0.385	0.384	0.001	53.989	53.831	53.831	0.4
  	(non-transfected cells)	0.383			53.674
  	Control oligo-	0.278	0.266	0.018	37.15	35.186	35.186	6.7
  	transfected cells 5	0.253			33.221
  	μg/mL
  	Control oligo-	0.348	0.352	0.006	48.155	48.785	48.785	1.6
  	transfected cells 2.5	0.356			49.415
  	μg/mL
  	Control oligo-	0.386	0.378	0.012	54.147	52.806	52.806	3.2
  	transfected cells 1.25	0.369			51.464
  	μg/mL
  	TNFRI anti-sense	0.117	0.113	0.006	11.533	10.79	10.79	5.7
  	oligo-transfected cells 5	0.108			10.047
  	μg/mL
  	TNFRI anti-sense	0.254	0.245	0.013	33.378	31.962	31.962	5.2
  	oligo-transfected cells	0.236			30.546
  	2.5 μg/mL
  	TNFRI anti-sense	0.321	0.311	0.015	43.907	42.257	42.257	4.8
  	oligo-transfected cells	0.3			40.607
  	1.25 μg/mL
  007	Control	0.368	0.367	0.002	51.306	51.07	51.07	0.6
  	(non-transfected cells)	0.365			50.833
  	Control oligo-	0.226	0.219	0.01	28.97	27.866	27.866	4.5
  	transfected cells 5	0.212			26.761
  	μg/mL
  	Control oligo-	0.293	0.272	0.03	39.507	36.128	36.128	11.2
  	transfected cells 2.5	0.25			32.749
  	μg/mL
  	Control oligo-	0.308	0.286	0.032	41.864	38.329	38.329	11.1
  	transfected cells 1.25	0.263			34.793
  	μg/mL
  	TNFRI anti-sense	0.123	0.114	0.013	12.517	10.949	10.949	11.8
  	oligo-transfected cells 5	0.104			9.382
  	μg/mL
  	TNFRI anti-sense	0.269	0.243	0.037	35.736	31.565	31.565	15.5
  	oligo-transfected cells	0.216			27.393
  	2.5 μg/mL
  	TNFRI anti-sense	0.313	0.303	0.014	42.65	41.078	41.078	4.7
  	oligo-transfected cells	0.293			39.507
  	1.25 μg/mL
  014	Control	0.377	0.38	0.004	52.726	53.2	53.2	1.1
  	(non-transfected cells)	0.383			53.674
  	Control oligo-	0.251	0.249	0.003	32.907	32.592	32.592	1.1
  	transfected cells 5	0.247			32.277
  	μg/mL
  	Control oligo-	0.338	0.315	0.033	46.581	42.887	42.887	10.6
  	transfected cells 2.5	0.291			39.193
  	μg/mL
  	Control oligo-	0.356	0.347	0.013	49.415	47.919	47.919	3.9
  	transfected cells 1.25	0.337			46.424
  	μg/mL
  	TNFRI anti-sense	0.11	0.104	0.008	10.378	9.379	9.379	8.2
  	oligo-transfected cells 5	0.098			8.379
  	μg/mL
  	TNFRI anti-sense	0.211	0.206	0.008	26.603	25.733	25.733	3.8
  	oligo-transfected cells	0.2			24.864
  	2.5 μg/mL
  	TNFRI anti-sense	0.3	0.294	0.008	40.607	39.664	39.664	2.9
  	oligo-transfected cells	0.288			38.722
  	1.25 μg/mL
  015	Control	0.475	0.469	0.009	68.284	67.246	67.246	2
  	(non-transfected cells)	0.462			66.209
  	Control oligo-	0.278	0.279	0.001	37.15	37.308	37.308	0.5
  	transfected cells 5	0.28			37.465
  	μg/mL
  	Control oligo-	0.34	0.343	0.004	46.896	47.289	47.289	1
  	transfected cells 2.5	0.345			47.683
  	μg/mL
  	Control oligo-	0.419	0.413	0.009	59.37	58.34	58.34	2.2
  	transfected cells 1.25	0.406			57.31
  	μg/mL
  	TNFRI anti-sense	0.13	0.125	0.007	13.658	12.842	12.842	5.7
  	oligo-transfected cells 5	0.12			12.025
  	μg/mL
  	TNFRI anti-sense	0.253	0.262	0.012	33.221	34.557	34.557	4.6
  	oligo-transfected cells	0.27			35.893
  	2.5 μg/mL
  	TNFRI anti-sense	0.377	0.381	0.005	52.726	53.279	53.279	1.3
  	oligo-transfected cells	0.384			53.831
  	1.25 μg/mL
  23	Control	0.260	0.255	0.008	40.591	39.632	39.632	3.1
  	(non-transfected cells)	0.249			38.672
  	Control oligo-	0.191	0.184	0.010	28.560	27.339	27.339	5.4
  	transfected cells 5	0.177			26.117
  	μg/mL
  	Control oligo-	0.216	0.209	0.009	32.919	31.786	31.786	4.4
  	transfected cells 2.5	0.203			30.653
  	μg/mL
  	Control oligo-	0.222	0.222	0.000	33.965	33.965	33.965	0.0
  	transfected cells 1.25	0.222			33.965
  	μg/mL
  	TNFRI anti-sense	0.107	0.106	0.001	13.798	13.620	13.620	1.3
  	oligo-transfected cells 5	0.105			13.441
  	μg/mL
  	TNFRI anti-sense	0.206	0.187	0.027	31.176	27.860	27.860	14.4
  	oligo-transfected cells	0.168			24.544
  	2.5 μg/mL
  	TNFRI anti-sense	0.213	0.212	0.001	32.396	32.222	32.222	0.7
  	oligo-transfected cells	0.211			32.048
  	1.25 μg/mL
  486	Control	0.249	0.249	0.001	41.244	41.148	41.148	0.3
  	(non-transfected cells)	0.248			41.053
  	Control oligo-	0.149	0.136	0.018	22.401	19.981	19.981	13.5
  	transfected cells 5	0.123			17.560
  	μg/mL
  	Control oligo-	0.246	0.231	0.022	40.672	37.732	37.732	9.5
  	transfected cells 2.5	0.215			34.792
  	μg/mL
  	Control oligo-	0.263	0.253	0.015	43.915	41.913	41.913	5.9
  	transfected cells 1.25	0.242			39.911
  	μg/mL
  	TNFRI anti-sense	0.071	0.068	0.004	7.917	7.361	7.361	6.2
  	oligo-transfected cells 5	0.065			6.805
  	μg/mL
  	TNFRI anti-sense	0.142	0.142	0.000	21.096	21.096	21.096	0.0
  	oligo-transfected cells	0.142			21.096
  	2.5 μg/mL
  	TNFRI anti-sense	0.193	0.179	0.021	30.644	27.924	27.924	11.5
  	oligo-transfected cells	0.164			25.204
  	1.25 μg/mL
  13	Control	0.211	0.209	0.003	34.037	33.659	33.659	1.4
  	(non-transfected cells)	0.207			33.282
  	Control oligo-	0.134	0.134	0.01	19.606	19.513	19.513	0.5
  	transfected cells 5	0.133			19.420
  	μg/mL
  	Control oligo-	0.195	0.188	0.011	31.020	29.611	29.611	5.7
  	transfected cells 2.5	0.180			28.201
  	μg/mL
  	Control oligo-	0.207	0.192	0.022	33.282	30.366	38.329	11.4
  	transfected cells 1.25	0.176			27.451
  	μg/mL
  	TNFRI anti-sense	0.087	0.080	0.010	10.882	9.585	9.585	12.4
  	oligo-transfected cells 5	0.073			8.288
  	μg/mL
  	TNFRI anti-sense	0.156	0.135	0.030	23.708	19.706	19.706	22.6
  	oligo-transfected cells	0.113			15.703
  	2.5 μg/mL
  	TNFRI anti-sense	0.208	0.174	0.048	33.470	27.097	27.097	27.6
  	oligo-transfected cells	0.140			20.723
  	1.25 μg/mL
  *Note:
  OD—optical density;
  SD—Standard Deviation;
  CV %—% Coefficient of Variance

• From the above data shown in Table 3, the mean TNFRI expression, in picograms per 1×10⁶cells, was determined for non-transfected (control) mesenchymal stem cells, as well as mesenchymal stem cells transfected with 1.25, 2.5, or 5 μl/ml of antisense or sense oligonucleotides. The mean TNFRI expression values are given in Table 4 below.

• TABLE 4
  TNFRI expression by hMSCs transfected with anti-sense and control
  (sense) oligonucleotides: summary for 7 tested hMSC donors

  	TNFRI expression in pg per 1 × 106cells
  	hMSC donor #:	Mean for

  	486	13	24	007	14	15	23	7 donors	SD

  Control (non-	41*	34	54	51	53	67	40	48.57	11.09
  transfected cells)
  TNFRI anti-sense	7	10	11	11	9	13	14	10.71	2.36
  oligo-transfected
  cells 5 μg/mL
  TNFRI anti-sense	21	20	32	32	26	35	28	27.71	5.74
  oligo-transfected
  cells 2.5 μg/mL
  TNFRI anti-sense	28	27	42	41	40	53	32	37.57	9.22
  oligo-transfected
  cells 1.25 μg/mL
  Control (sense)	20	20	35	28	33	37	27	28.57	6.85
  oligo-transfected
  cells 5 μg/mL
  Control (sense)	38	30	49	36	43	47	32	39.29	7.30
  oligo-transfected
  cells 2.5 μg/mL
  Control (sense)	42	30	53	38	48	58	34	43.29	10.21
  oligo-transfected
  cells 1.25 μg/mL
  *Note:
  These values represent mean TNFRI numbers (from table 3, column 8: “TNFRI in pg per 1 × 106cells”) rounded to whole numbers

• A second group of transfected cells was used for investigation of the effect of hMSCs on hPBMC proliferation in vitro. Human PBMCs from two different donors were used for this assay. PBMCs were isolated from leukopheresed blood using Ficoll-Paque gradient centrifugation according to the manufacturer's protocol (Amersham Biosciences, Ficoll-Paque Plus product insert). Cells were stored frozen at −80° C. in a medium including 90% FBS and 10% DMSO prior to analysis. On the day of the experiment hPBMCs were thawed, counted and plated into 96-well tissue culture plates at 1×10⁵cells/well together with hMSCs (1×10⁴cells/well). A combination of anti-CD3 (1 μg/mL) and anti-CD28 (1 pg/mL) antibodies was used to stimulate lymphocyte proliferation that represents an in vitro model for immune cell activation characteristics of GVHD and rejection of allogeneic organs. (Trickett, et al.,J. Immunol. Methods, Vol. 275, pgs. 251-255 (2003); Koulova, et al.,J. Exp. Med., Vol. 173, No. 3, pgs. 759-762 (1991); Foster, et al.,Transplantation, Vol. 76, No. 6; Czitrom,Clin. Ortho. Relat. Res., Vol. 326, pgs. 11-24 (1996)). The plates then were incubated in a humidified atmosphere containing 5% CO₂. The proliferation of PBMCs alone and in the presence of MSCs was measured atday 5 from culture initiation by the addition of [Methyl-³H]-thymidine at 1 μCi/well for the final 18-20 hrs of culture. After labeling, the cells were transferred onto a glass filter using a 96-well plate harvester, and radioactivity incorporated into DNA was measured by a liquid scintillation beta-counter. The uptake of [Methyl-³H]-thymidine into DNA in counts per minute (cpm) represents hPBMC proliferation. Final results were expressed as % inhibition of PBMC proliferation in the presence of MSCs calculated as:
• 
  100%−[Proliferation (PBMC+MSC, cpm)×100/Proliferation (PBMC, cpm)]
• The results for the mesenchymal stem cells from each of the donors are given in Table 5 below.

• TABLE 5
  Inhibition of CD3/CD28-induced hPBMC proliferation by hMSCs transfected with anti-sense
  and control (sense) oligonucleotides: summary for 7 tested hMSC donors

  	% inhibition of hPBMC proliferation by hMSCs
  	hMSC donor #:	Mean %

  486

  13

  24

  007

  14

  15

  23

  for 7

  hPBMC donor #:	2	3	2	3	3	3	3	2	2	3	donors	SD

  Control (non-	65	73	82	94	70	66	82	62	68	91	75.30	11.26
  transfected cells)
  TNFRI anti-sense	40	45	46	68	32	10	39	19	38	52	38.90	16.29
  oligo-transfected
  cells 5 μg/mL
  TNFRI anti-sense	83	90	59	86	ND	73	ND	63	47	58	69.88	15.48
  oligo-transfected
  cells 2.5 μg/mL
  TNFRI anti-sense	62	74	86	ND	72	64	57	ND	72	80	70.88	9.58
  oligo-transfected
  cells 1.25 μg/mL
  Control (sense)	38	87	60	77	58	77	62	44	52	53	60.80	15.50
  oligo-transfected
  cells 5 μg/mL
  Control (sense)	60	91	67	ND	ND	62	66	57	70	95	71.00	14.22
  oligo-transfected
  cells 2.5 μg/mL
  Control (sense)	87	ND	68	71	66	68	36	ND	49	85	70.57	12.77
  oligo-transfected
  cells 1.25 μg/mL
  Note:
  ND—no data

• The above data with respect to inhibition of CD3/CD28 induced PBMC proliferation were correlated to the mean TNFRI expression data shown in Table 4 hereinabove. The correlated data with respect to mean TNFRI expression and inhibition of CD3/CD28 induced PBMC proliferation are given in Table 6 below.

• TABLE 6
  TNFRI expression and effect on hPBMC proliferation in
  vitro by hMSCs transfected with TNFRI oligonucleotides

  		% Inhibition of	TNFRI
  	Oligonucleotide	hPBMC	expression in
  	concentration	proliferation	pg/1 × 106MSCs
  Human MSCs condition	(μg/mL)	(Mean ± SD)	(Mean ± SD)
  Untransfected (Control	Not applicable	75.30 ± 11.26	48.57 ± 11.09
  MSCs)
  Antisense oligonucleotide	1.25	70.88 ± 9.58	37.57 ± 9.22
  	2.5	69.88 ± 15.48	27.71 ± 5.74
  	5	38.90 ± 16.29	10.71 ± 2.36
  Sense oligonucleotide	1.25	70.57 ± 12.77	43.29 ± 10.21
  (control oligonucleotide)	2.5	71.00 ± 14.22	39.29 ± 7.30
  	5	60.80 ± 15.50	28.57 ± 6.85

• The results from these experiments show that hMSCs with decreased expression of TNFR type I (TNFRI) lose their ability to suppress hPBMC proliferation in vitro. The data support the premise that the expression of TNFRI is an essential link to the suppression of PBMC proliferation by MSCs. Thus, TNFRI can be used as a potency marker for MSC immunomodulative activity. Based on the obtained data, a potency threshold of 13.07 pg of TNFRI (mean±SD) per 1×10⁶cells correlates with less than 50% inhibition of hPBMC proliferation (Table 6,FIG. 1). Thus, non-potent MSCs are cells expressing less than 13 pg TNFRI per 1×10⁶cells.
EXAMPLE 2TNFRI is a Temperature-Sensitive Marker of hMSC Functionality
• Ex vivo handling of mammalian cells is restricted by a number of factors including temperature. For example, low temperatures such as −80±5° C., or lower, even as low as −135° C. or below (liquid nitrogen) are required for cell storage whereas ex vivo cell expansion requires a temperature of 37±0.5° C. Cell exposure to temperatures outside of the optimal ranges may lead to a decrease in cell functionality or cell death. Mammalian cells are able to withstand short-term minor temperature fluctuations; however, each type of cells has its own temperature tolerance range for cell culture maintenance, shipping, and storage.
• The expression level of TNFRI on hMSCs correlates with hMSC immunosuppressive activity. The level of TNFRI expression by hMSCs of less than 13 pg/10⁶cells has been determined as a threshold, below which hMSCs begin to lose their ability to suppress an immune response (SeeFIG. 1). Thus, TNFRI expression is a marker of hMSC immunosuppression, an activity that is believed essential for MSCs to be efficacious for treatment of immunological reactions taking place in GVHD, organ rejection, autoimmune diseases, and other diseases. Here, effects of temperature fluctuations during storage of frozen hMSCs as well as the effect of time of exposure of cells to room temperature on expression of TNFRI on hMSCs was investigated.
• Effect of Store Temperature Fluctuations on TNFRI Expression and hMSC immunosuppressive potential.
• The objective of these experiments was to investigate the ability of hMSCs to retain their functional characteristics after an exposure to temperatures above −80° C., which are not optimal temperatures for storage of frozen cells. Human MSCs were frozen atpassage 5 and placed for storage in a freezer at −80±5° C. After several weeks, bags of frozen cells were removed from the −80±5° C. freezer and placed at either −70±5° C., −60±5° C., or −50±5° C. for 72±2 hours. After 72±2 hours, the bags were returned to storage at −80±5° C. for at least 24 hours before thaw and analysis. A set of bags moved from one −80±5° C. freezer to another, following the same schedule as the other bags, served as a control. On the day of the experiment the bags containing the cells were thawed, cells were counted, and cell lysates for the TNFRI ELISA were prepared as described in Example 1. The TNFRI ELISA was performed as described in Example 1. Results are summarized inFIG. 2 (bars show mean TNFRI values ±SD for 3 hMSC bags). The data showed that exposure of hMSCs to temperatures of −60±5° C. or −50±5° C. decreases the TNFRI expression level: the level of TNFRI detected by ELISA was below the determined hMSC potency threshold of 13 pg/10⁶cells (represented by the solid line on the graph).
• Parallel with TNFRI measurement, two bags with hMSCs stored at −80±5° C. (optimal storage temperature served as a control) and at −50±5° C. (corresponding to a ±30° C. greater than the −80±5° C. optimal storage temperature) were used for investigation of hMSC immunosuppressive activity. The ability of the MSCs to suppress anti-CD3/CD28-induced proliferation of hPBMCs in vitro was evaluated as described in Example 1. The results showed that hMSCs stored at −50±5° C. lost their ability to suppress hPBMC proliferation, whereas cells stored at −80±5° C. inhibited hPBMC proliferation by 92% (FIG. 3, dark bars represent mean±SD % inhibition of hPBMC proliferation. Numbers inside the dark bars show numerical values). The immunosuppressive activity of MSCs is dependent on the level of TNFRI expression: cells expressing more than 13 pg/10⁶cells of TNFRI, which was determined as an MSC immunosuppressive potential threshold, are biologically active, and cells with the TNFRI level below 13 pg/10⁶cells are not (FIG. 3, light bars represent mean±SD of the TNFRI expression level. Numbers inside the light bars show numerical values). Thus, non-optimal storage temperatures decrease TNFRI expression on hMSCs, and which correlates with decrease in hMSC functionality.
• Effect of Cell Exposure Time to Room Temperature on TNFRI Expression on hMSC.
• The results of this experiment serve as additional evidence that TNFRI expression on hMSCs is decreasing under cell exposure to non-optimal temperatures. In this experiment the effect of cell suspension storage at room temperature on TNFRI expression was studied. Two hMSC lots were used in the experiment. Bags containing hMSCs were stored at ≦−135° C. prior to the experiment. On the day of the experiment the cells were thawed and diluted with Plasmalyte A physiological solution (Baxter) in a manner that mimics the current cell processing for intravenous hMSC administration at clinical sites. The thawed and diluted hMSCs were kept at room temperature (22° C.-24° C.), and samples were taken and tested for the amount of TNFRI at 0 (immediately post-thaw-baseline), 6, 8, 10, 24, and 32 hours post-thawing. The results showed that exposure of hMSCs to room temperature decreased the TNFRI expression level on the hMSCs (FIG. 4, bars represent mean±SD of the TNFRI expression level for 2 hMSC lots. The solid line represents the TNFRI expression level of 13 pg/10⁶cells, which is the hMSC potency threshold). The significant decrease in TNFRI expression was observed at 24 hours and 32 hours, and it correlated with a significant decrease in cell viability (below 20%, data not shown).
• Thus, the experiments described above show that TNFRI expression by hMSCs is sensitive to temperature, and TNFRI can be used as a marker of functionality of hMSC that were exposed to non-optimal temperatures during storage, shipping or cell processing.
• The disclosures of all patents, publications, including published patent applications, depository accession numbers, and database accession numbers are hereby incorporated by reference to the same extent as if each patent, publication, depository accession number, and database accession number were specifically and individually incorporated by reference.
• It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims.

Claims (25)

1-9. (canceled)

10. A composition comprising allogeneic mesenchymal stem cells wherein said mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 27 pg/10⁶cells.

11. The composition ofclaim 10, wherein said mesenchymal stem cells are human mesenchymal stem cells.

12. The composition ofclaim 10, wherein said mesenchymal stem cells are bone marrow-derived.

13. The composition ofclaim 10, wherein said mesenchymal stem cells are exposed to at least one freeze-thaw cycle.

14. The composition ofclaim 10, wherein said mesenchymal stem cells are expanded in culture.

15. The composition ofclaim 14, wherein said mesenchymal stem cells are expanded for three to eight passages.

16. The composition ofclaim 15, wherein said mesenchymal stem cells are expanded for four to six passages.

17. The composition ofclaim 16, wherein said mesenchymal stem cells are expanded for five passages.

18. The composition ofclaim 10, further comprising an acceptable pharmaceutical carrier.

19. The composition ofclaim 10, further comprising dimethyl sulfoxide.

20. A method of treating an immunological response in a patient comprising:

administering to said patient allogeneic mesenchymal stem cells, wherein said mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 13 pg/10⁶cells.

21. The method ofclaim 20, wherein said mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 18 pg/10⁶cells.

22. The method ofclaim 21, wherein said mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 27 pg/10⁶cells.

23. The method ofclaim 20, wherein said mesenchymal stem cells are human mesenchymal stem cells.

24. The method ofclaim 20, wherein said immunological response is associated with an autoimmune disease.

25. The method ofclaim 24, wherein said autoimmune disease is from the group consisting essentially of rheumatoid arthritis, multiple sclerosis, Type I diabetes, Guillain-Barré syndrome, lupus erythematosus, myasthenia gravis, optic neuritis, psoriasis, Graves' disease, Hashimoto's disease, Ord's thyroiditis, aplastic anemia, Reiter's syndrome, autoimmune hepatitis, primary biliary cirrhosis, antiphospholipid antibody syndrome, opsoclonus myoclonus syndrome, temporal arteritis, acute disseminated encephalomyelitis, Good pasture's syndrome, Wegener's granulomatosis, coeliac disease, pemphigus, polyarthritis, warm autoimmune hemolytic anemia, and scleroderma.

26. The method ofclaim 20, wherein said immunological response is associated with Crohn's disease.

27. The method ofclaim 20, wherein said immunological response is associated with graft versus host disease.

28. A method of determining immunosuppressive potency of a population of mesenchymal stem cells comprising:

obtaining a sample from the population of mesenchymal stem cells;

quantifying TNF-α receptor Type I expression in the sample to obtain a measured value; and

comparing the measured value to a threshold value.

29. The method ofclaim 28, wherein said threshold value is at least 13 pg/10⁶cells.

30. The method ofclaim 29, wherein said threshold value is at least 18 pg/10⁶cells.

31. The method ofclaim 30, wherein said threshold value is at least 27 pg/10⁶cells.

32. The method ofclaim 28, wherein TNF-α receptor Type I expression is quantified using an enzyme-linked immunosorbent assay.

33. The method ofclaim 28, further comprising lysing cells in the sample prior to quantifying TNF-α receptor Type I expression.

Images